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Mucosal SIV vaccines comprising inacti-
vated virus particles and bacterial adju-
vants induce CD8+ T-regulatory cells
that suppress SIV positive CD4+ T-cell
activation and prevent SIV infection in
the macaque model
by Andrieu JM, Chen S, Lai C, Guo W,
Lu W. Front Immunol (2014) 5:297. doi:
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In the current issue of Frontiers in
Immunology, Jean-Marie Andrieu and col-
laborators, report results from non-human
primate experiments designed to explore
a new vaccine concept aimed at induc-
ing tolerance to the simian immunode-
ficiency virus (SIV) (1). This approach,
which is significantly different from other
vaccine concepts tested to date, resulted in
a surprisingly high level of protection. If
the results are confirmed and extended to
the human immunodeficiency virus (HIV),
this approach may represent a game chang-
ing strategy, which should be welcomed
by a field that has been marred by mostly
disappointing results.
When HIV was discovered and estab-
lished as the cause of the Acquired Immune
Deficiency Syndrome (AIDS) in 1983–
1984, there was an expectation that a pre-
ventive vaccine would be rapidly developed
(2).
Vaccines against several major human
viral diseases (polio, measles, mumps,
rubella, etc.) were successfully developed
during the preceding two or three decades,
mostly using live-attenuated viruses, and
designed to induce the same type of pro-
tective immune responses that develop
after natural infection. Moreover, recent
advances in molecular biology and recom-
binant DNA technologies were offering
exciting new opportunities for vaccine
development, first achieved with the licen-
sure in 1986 of a recombinant vaccine
against hepatitis B (3, 4).
Since the use of whole-inactivated or
of live-attenuated vaccines was considered
too risky for a pathogen such as HIV, the
molecular approach was the one selected
by early HIV vaccine developers. That deci-
sion was also based on the confidence that
new knowledge on the structure and func-
tion of the virus, as well as of the pathogen-
esis of the disease, will provide the informa-
tion needed for the rational development
of a much needed HIV vaccine (5).
In that environment of optimism, the
first phase I clinical trials of HIV vac-
cines started in the United States in 1988.
Since then, more than 200 clinical trials
have been conducted globally, the major-
ity of them phase I and II trials, to assess
the safety and immunogenicity of different
vaccine candidates. Those candidate vac-
cines were developed and tested according
to prevailing paradigms that sequentially
explored the role of neutralizing antibod-
ies, cell-mediated immunity (CMI) and,
more recently, other potential mechanisms
of immune protection (2, 6).
Although much has been learned from
those small-scale clinical trials, the results
from phase IIb/III efficacy trials are the
ones that have driven major changes on
how HIV vaccine research is advanced.
Those trials have also given us a few sur-
prises. Fortunately, the field has been able
to learn from those lessons and steadily
move forward.
Perhaps the first major surprise was
when in 1994 we learned that field isolates
of HIV were more difficult to neutralize
in vitro than laboratory-adapted strains,
and that proposed existing candidate vac-
cines could not induce the appropriate type
of neutralizing antibodies, a problem that
we are still struggling to solve. Nevertheless,
in the early 2000s, two gp120 candidate vac-
cines from VaxGen were tested in efficacy
trials and, as many predicted, they failed to
protect. That failure shifted the field to CMI
vaccines and to the suggestion that perhaps
the best that an HIV vaccine could do is
to decrease virus load in vaccinated indi-
viduals who became infected (7). Unfor-
tunately, the STEP study, which tested the
CMI concept using an adenovirus 5 vec-
tor, and which was a favorite approach of
the HIV vaccine community, was halted in
2007 because of lack of efficacy (8). That
was a major surprise that led to calls to slow
down clinical trials and to go back to basic
science (9).
The next major surprise came in 2009,
when the results from the Thai RV144
were announced. The trial, which evaluated
a canarypox prime followed by a gp120
boost, was strongly opposed by some of
the leading HIV vaccine scientists (10).
Unexpectedly, the trial showed for the first
time that prevention of HIV infection was
achievable by an HIV vaccine (11). In a
commentary authored by the late Nor-
man Letvin (12), who himself expressed
concerns about the conduct of the RV144
trial, he indicated that the findings were
not expected based on preclinical stud-
ies and human immunogenicity data, con-
cluding with the lapidary remark that “we
have learned to expect the unexpected in our
efforts to generate an effective HIV vaccine.”
Although the observed protection in
RV144 was modest (31.2%), those results
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not only brought new optimism to the field,
but also triggered a major collaborative
effort to try to identify immune correlates
of protection (13). In this regard, novel and
more promising vaccines are being devel-
oped that may result in higher levels of
protective efficacy, including the use of vec-
tors based on adenovirus 26 (Ad26) and
cytomegalovirus (CMV) (14, 15).
Another surprise came when a careful
statistical analysis of the step study con-
firmed that vaccination in fact enhanced
HIV acquisition among a subset of the
volunteers (16), an observation that was
also been made in the Phambili study con-
ducted in South Africa using the same
vaccine as in the step study (17). The
most likely explanation of the observed
enhancement is a specific immune acti-
vation induced by the adenovirus 5 vec-
tored vaccines. Although the mechanism
is poorly understood, it does not seem to
be present with another adenovirus 5 vec-
tored HIV vaccine (18), and it is not clear
how relevant it could be to other vaccine
approaches (19). Nevertheless, it is well-
known that activation of CD4+ cells is
important for HIV replication, which cre-
ates a dilemma for vaccinologists, who have
to thread a compromise between the desire
to induce strong vaccine responses and, at
the same time, avoid the immune activa-
tion that may enhanced HIV acquisition. In
this and other regards, HIV/AIDS is differ-
ent from other viral diseases for which vac-
cines have been developed, because forces
vaccine developers to explore mechanisms
that nature has not developed, especially
when dealing with chronic infections (20).
It is in this context that Jean-Marie
Andrieu and collaborators report in this
journal (1) additional results from an
approach that they first reported in 2012
(21, 22).
The investigators used Chinese
macaques to explore the concept that
the induction of immune tolerance to SIV
induces protective immunity in the absence
of usual humoral or cellular immune
responses. To achieve that goal, inacti-
vated SIV was intragastrically administered
together with living bacterial adjuvants
(BCG, Lactobacillus plantarum, or Lac-
tobacillus rhamnosus) with the goal of
inducing tolerance to the SIV antigens. In
a series of experiments, the investigators
showed that their approach protected the
experimental animals from mucosal and
parenteral challenges. Vaccination neither
elicit SIV-specific antibodies nor cytotoxic
T-lymphocytes but induced a previously
unrecognized population of non-cytolytic
MHCIb/E-restricted CD8+ T regula-
tory cells that suppressed the activation
of SIV positive CD4+ T-lymphocytes.
Although the number of monkeys is rel-
atively small, the levels of protection are
impressive, with 23 out of 24 animals pro-
tected in one of the experiments, when
animals were challenged 48 months after
vaccination.
The 2012 publication from this group
(21) had very little impact in the field, per-
haps because it was received with a degree
of skepticism. After all, 30 years of intense
vaccine research had not resulted in a prac-
tical effective vaccine, although an HIV
vaccine is sorely needed to bring the HIV
epidemic under control. No stone should
remain unturned in its search, and the
approach reported in this journal should
not be dismissed a priori. Instead, it should
be carefully considered by other scientists
and appropriately confirmed or refuted by
additional research.
In order to accelerate the develop-
ment of an HIV vaccine, one of us has
proposed a number of actions, includ-
ing the suggestion to establish a pro-
gram of truly innovative research with
protected funding to explore out-of-the-
paradigm approaches, perhaps allocating
to this program not <10% of the total
HIV vaccine investment (23). Out-of-the-
paradigm approaches, such as the one pro-
posed by Andrieu et al., should be further
explored (24).
Paraphrasing Dean K. Simonton (25),
the University of California psychologist
who has dedicated his professional life to
the study of creativity: good science con-
tributes ideas that are original and useful,
and we have plenty of those in the HIV vac-
cine field. However, the solution to the HIV
vaccine challenge will require genius which,
according to Simonton, is characterized not
only by originality and usefulness, but also
by surprising results.
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